Monitoring high-dose heparinization during cardiopulmonary bypass – A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays

Summary

Heparinization requires monitoring, but optimal methods for measuring the anticoagulant effects of heparin remain to be determined. We compared prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity (anti-Xa) assays in monitoring high-dose heparinization during cardiopulmonary by-pass (CPB). Heparin effects were serially measured with PiCT and two anti-Xa assays in 100 patients. Antithrombin and protein C activities were measured preoperatively, and antithrombin activity was measured during CPB. Activation of coagulation was assessed with measurements of prothrombin fragment F1+2, soluble fibrin complexes, and D-dimer before, during, and after CPB. During CPB mean ranges of PiCT and of anti-Xa heparin levels measured with (anti-Xa A) and without (anti-Xa B) dextran sulfate and antithrombin supplementation were 5.0–5.2, 4.7–5.0, and 4.5–4.9 IU/ml, respectively. There was poor agreement between PiCT and anti-Xa and between the two anti-Xa assays (r=0.32–0.65 and broad limits of agreement). Patients with low preoperative antithrombin or protein C levels had lower PiCT (p=0.028 and p=0.01) and anti-Xa A (both p<0.001) levels during CPB than others. Patients with the lowest heparin activities during CPB (lowest deciles of PiCT and anti-Xa A) had higher subsequent F1+2 after CPB (p=0.002 and p=0.02), and patients with high heparin levels required fewer transfusions of packed red blood cells than others. In conclusion, in the challenging setting of CPB there is poor agreement between anti-Xa assays and PiCT. However, coagulation-based PiCT could provide an alternative to the chromogenic anti-Xa assays. Higher heparin levels during CPB were confirmed to associate with reduced transfusion requirements.

keywords

Heparin - blood coagulation tests - antithrombin - protein C - thrombosis - cardiopulmonary by-pass

• References

• 1 Hirsh J, Raschke R. Heparin and low-molecularweight heparin. The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S-203S.
• 2 Hirsh J, Anand SS, Halperin JL. et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1094-1096.
• 3 Culliford AT, Gitel SN, Starr N. et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193: 105-111.
• 4 Kovacs MJ, Keeney M, Mac Kinnon K. et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21: 55-60.
• 5 Kitchen S, Iampietro R, Woolley AM. et al. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability. Thromb Haemost 1999; 82: 1289-1293.
• 6 Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: Relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000; 11: 137-144.
• 7 Calatzis A, Spannagl M, Gempeler-Messina P. et al. The prothrombinase induced clotting test. A new technique for the monitoring of anticoagulants. Haemostasis 2000; 30 (Suppl. 02) 172-174.
• 8 Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Haemost 2002; 28: 361-368.
• 9 Raivio P, Kuitunen A, Suojaranta-Ylinen R. et al. Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage. J Thromb Haemost 2006; 4: 1523-1529.
• 10 Hardy JF, Belisle S, Robitaille D. et al. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996; 112: 154-161.
• 11 Despotis GJ, Joist JH, Goodnough LT. et al. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1997; 113: 611-613.
• 12 Gruenwald C, de Souza V, Chan AK. et al. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Perfusion 2000; 15: 203-209.
• 13 Lyon SG, Lasser EC, Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration. Thromb Haemost 1987; 58: 884-887.
• 14 Sobel M, Mc Neill PM, Carlson PL. et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793.
• 15 Cella G, Vittadello O, Gallucci V. et al. The release of beta-thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. Eur J Clin Invest 1981; 11: 165-169.
• 16 Valen G, Blomback M, Sellei P. et al. Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery. Thromb Res 1994; 73: 21-29.
• 17 Mouton C, Calderon J, Janvier G. et al. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine. Thromb Res 2003; 111: 273-279.
• 18 Chandler WL, Patel MA, Gravelle L. et al. Factor XIIIa and clot strength after cardiopulmonary bypass. Blood Coagulation Fibrinol 2001; 12: 101-108.
• 19 Young E, Podor TJ, Venner T. et al. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997; 17: 1568-1574.
• 20 Weitz JI, Hudoba M, Massel D. et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
• 21 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
• 22 Adams MJ, Cardigan RA, Marchant WA. et al. Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2002; 16: 59-63.
• 23 Donahue BS, Gailani D, Mast AE. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost 2006; 4: 1011-1016.
• 24 Kojima T, Gando S, Kemmotsu O. et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: Role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001; 15: 60-64.
• 25 Petäjä J, Fernández JA, Gruber A. et al. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 1997; 99: 2655-2663.
• 26 Raivio P, Fernández JA, Kuitunen A. et al. Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 33: 44-51.
• 27 Despotis GJ, Joist JH, Hogue Jr CW. et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46-54.
• 28 Koster A, Fischer T, Praus M. et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: Impact of heparin management. Anesthesiology 2002; 97: 837-841.
• 29 Despotis GJ, Joist JH, Hogue Jr CW. et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-908.